| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | CSGALNACT1; CHGN; GALNACT1; Chondroitin sulfate N-acetylgalactosaminyltransferase 1; CsGalNAcT-1; Chondroitin beta-1; 4-N-acetylgalactosaminyltransferase 1; Beta4GalNAcT-1 |
| Entrez GeneID | 55790 |
| WB Predicted band size | Calculated MW: 61 kDa; Observed MW: 61 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | The antiserum was produced against synthesized peptide derived from human CSGALNACT1. AA range:201-250 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于 β4 GalNAc-T1(B4GALNT1)抗体的模拟参考文献示例(非真实文献，仅供格式参考)：
---
1. **文献名称**: *"Development of a Monoclonal Antibody Specific for Human β4 GalNAc-T1 and Its Application in Glycosylation Studies"*
**作者**: Suzuki T, et al.
**摘要**: 本研究报道了一种针对人源β4 GalNAc-T1的高特异性单克隆抗体的开发，通过免疫印迹和免疫组化验证其在多种组织中的表达模式，证实该抗体可用于研究酶在肿瘤相关糖基化修饰中的功能。
2. **文献名称**: *"Aberrant Expression of β4 GalNAc-T1 in Colorectal Cancer Detected by Novel Polyclonal Antibodies"*
**作者**: Wang Y, et al.
**摘要**: 利用新开发的多克隆抗体，研究发现β4 GalNAc-T1在结直肠癌组织中显著上调，并与患者预后不良相关，提示其可能作为癌症生物标志物或治疗靶点。
3. **文献名称**: *"Role of β4 GalNAc-T1 in Ganglioside Biosynthesis Revealed by Antibody-mediated Inhibition in Neuronal Cells"*
**作者**: Hennet T, et al.
**摘要**: 通过抗体介导的功能抑制实验，揭示了β4 GalNAc-T1在神经节苷脂合成中的关键作用，并证明其缺失导致神经元细胞膜脂筏结构异常。
4. **文献名称**: *"Comparative Analysis of β4 GalNAc-T1 Antibody Specificity Across Species for Translational Research"*
**作者**: Zhang L, et al.
**摘要**: 该研究评估了多种β4 GalNAc-T1抗体的种属交叉反应性，为跨物种比较研究(如小鼠模型与人类疾病)提供了抗体选择依据，并验证了其在流式细胞术中的适用性。
---
**注意**：以上文献为模拟内容，实际研究中请通过数据库(如PubMed、Google Scholar)检索真实文献。建议使用关键词：**B4GALNT1 antibody**、**β4 GalNAc-T1 function**、**glycosylation marker** 等。
**Background of Beta-4 GalNAcT1 Antibody**
Beta-4 GalNAcT1 (β-1.4-N-acetylgalactosaminyltransferase 1), encoded by the *B4GALNT1* gene, is a glycosyltransferase involved in synthesizing glycosphingolipids, particularly gangliosides, by catalyzing the transfer of N-acetylgalactosamine (GalNAc) to glycosphingolipid acceptors. It plays a critical role in cell membrane composition, neural development, and cellular recognition processes. Dysregulation of B4GALNT1 is linked to neurological disorders, including hereditary spastic paraplegia (SPG26), and certain cancers.
Antibodies targeting Beta-4 GalNAcT1 are essential tools for studying its expression, localization, and function. These antibodies are typically developed in hosts like rabbits or mice using immunogenic peptides or recombinant protein fragments. They enable detection via techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF), aiding in research on ganglioside biosynthesis, neural pathologies, and cancer biomarkers. Validation often includes knockout cell lines or tissues to confirm specificity. Such antibodies contribute to understanding Beta-4 GalNAcT1's role in disease mechanisms and potential therapeutic targeting.
×
